ページ6 - 最高の結腸癌医師 - トップ136名の医師

Member of SICOB - Italian Society of Obesity Surgery and ACOI - Association of Italian Hospital Surgeons                                               

Dr Braun is a board-certified general surgeon with over 25 years of experience specializing in gastrointestinal surgery, particularly in the treatment of gastroesophageal reflux disease (GERD) through Fundoplication surgery. He has performed over 500 successful Nissen and Toupet Fundoplication procedures, with a focus on minimally invasive laparoscopic techniques. His expertise extends to diagnosing complex cases of GERD and offering comprehensive treatment plans to improve patient outcomes.

He has carried out his main training experiences in various international institutions and specialization courses in general and digestive system surgery, including a two-year training internship at Johns Hopkins University, Division of Hepatobiliary Pancreatic Surgery and numerous courses in Madrid, with Prof. E. Moreno Gonzales (Curso Internacional de Actualizaciòn en chirurgia General y del Aparato Digestivo) or in New Orleans (Medical Education at the 90th Annual Clinical Congress of the American College of Surgeons).

Dr. Braun has extensive expertise in the field of digestive surgery. He has focused on implementing advanced protocols and optimizing surgical techniques, while maintaining high standards of safety and patient care. He has collaborated with a multidisciplinary team to provide an integrated and personalized approach in the management of obese or digestive disorder patients, improving quality of life and reducing post-operative complications.

Education

Cumhuriyet University Faculty of Medicine, 2004
Istanbul Haydarpaşa Training and Research Hospital Internal Medicine Residency, 2010
Karadeniz Technical University Faculty of Medicine Medical Oncology Residency, 2015

Experience

MD Andeson Cancer Center, USA, 2008
Sunnybrook Odette Cancer Center Breast Cancer Clinic, Canada, 2017
Moffit Cancer Center , USA 2022
Istanbul Haydarpaşa Training and Research Hospital Internal Medicine, 2010
İdil State Hospital Internal Medicine Clinic, 2011
Karadeniz Technical Universityniversitesi Faculty of Medicine, Medical Oncology Clinic, 2015
Istanbul Göztepe Training and Research Hospital, Medical Oncology Clinic, 2018
Yeniyüzyıl University Gaziosmanpaşa Hospital, Medical Oncology Clinic, 2020
Ataşehir Medicana Hospital, Medical Oncology Clinic, 2022

Scientific Membership

Turkish Medical Association (TTB)
Turkish Society of Medical Oncology (TTOD)
European Society for Medical Oncology (ESMO)
American Society of Medical Oncology (ASCO)

Medical Intrests

• Breast Cancer
• Lung Cancer
• Colon Cancer
• Stomach Cancer
• Rectal Cancer
• Ovarian Cancer
• Liver Cancer
• Oesophageal Cancer - Oesophageal Cancer
• Kidney Cancer
• Larynx Cancer - Cancer of the Larynx
• Thyroid Cancer
• Head and Neck Cancers
• Gynaecological Cancers
• Pancreatic Cancer
• Oesophageal Cancer - Oesophageal Cancer
• Uterine Cancer
• Brain Cancers - Brain Tumours
• Soft Tissue Cancer - Sarcomas
• Prostate Cancer
• Bladder Cancer
• Bile Tract Cancer
• Testicular Cancer
• Cervical Cancer
• Mouth, Tongue, Lip Cancers
• Gastrointestinal System Cancers
• Bone Tumours
• Trachea and Bronchial Cancers
• Skin Cancers - Skin Cancers
• Skeletal System Tumours
• Gallbladder Cancer
• Mesothelioma

Areas of Interests

• Breast cancer
• Lung cancer
• Colorectal cancers
• Gynecological and urogenital cancers
• Molecular Oncology

Education:

• Kızıltepe Anatolian High School 2001
• Dicle University Faculty of Medicine 2007
• Istanbul Medeniyet University Göztepe Training and Research Hospital 2014
• Kartal City Hospital 2021
• Associate Professor of Medical Oncology 2023

Experience:

• Liv Hospital Ulus
• Adıyaman University Training and Research Hospital
• Istanbul Umraniye Training and Research Hospital
• Istanbul Umraniye Training and Research Hospital

Research:

• Phase II, Randomized, Open-Label, Multicenter Study to Comparatively Evaluate the Efficacy and Safety of GDC-9545 and Physician-Preferred Endocrine Monotherapy in Previously Treated, Estrogen Receptor Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer Patients, Other ( International), Dr. Murat Ayhan
• Phase III, Randomized, Evaluating the Efficacy and Safety of Palbociclib and Fulvestrant with Gdc-0077 Compared with Placebo in Patients with Pik3ca-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer. Double Blind, Placebo Controlled Study, Other (International), Dr. Murat Ayhan
• Randomized, Multicenter, Phase Ib/III Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Atezolizumab Compared to Intravenous Atezolizumab in Patients with Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Other (International) Dr. Murat Ayhan
• Randomized, Controlled, Multicenter, Open-Label Study Including Observation Follow-Up for PSMA-PET-Negative Patients, Investigating the Efficacy and Safety of Addition of Apalutamide to Radiotherapy and LHRH Agonist in PSMA-PET-Positive High-Risk Hormone-Sensitive Prostate Cancer Patients, Other (International) Dr. Murat Ayhan
• Biomarker Study to Identify Patients with Advanced Stage Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations-42756493BLC0002, Other (International), Dr. Murat Ayhan
• Publications:
• Ayhan M, Turan N, Köstek O, et all. Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology? Curr Probl Cancer. 2021 Jun;45(3):100670. doi: 10.1016/j.currproblcancer.2020.100670.
• Ayhan M, Odabas H, Turan N, et all. Factors affecting the mortality rate of patients with cancer hospitalized with COVID-19: a single center's experience. J Chemother. 2021 Nov;33(7):499-508. doi: 10.1080/1120009X.2021.1923153.
• Ayhan M, Laçin Ş, Özyükseler DT, et all. Does systemic anti-tumor therapy increase COVID-19 risk in patients with cancer? J Oncol Pharm Pract. 2021 Sep;27(6):1461-1467. doi: 10.1177/10781552211015762.
• Ayhan M, Abamor E, Coban Kokten S, et al. Value of FDG PET/CT in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. EJMI 2022;6(2):165–175.
• Ayhan M, Terzioglu K. Experience With Rapid Drug Desensitization With Chemotherapeutics; A SingleCentre Retrospective Study. EJMI 2021;5(3):380–387.
• Doğan A, AYHAN M. Survival analysis of patients with triple-negative breast cancer: a single-center experience. Journal of Oncological Sciences, 8(2), 94-99., Doi: 10.37047/jos.2022-89749
• Terzioğlu K, Ayhan M. Comparative Assessment of Platinum Salts and Taxane Group Hypersensitivity Reactions, The Role of Skin Tests in Diagnosis? J Oncol Pharm Pract. 2021 Nov 30:10781552211050084. doi: 10.1177/10781552211050084.
• Tacar SY, Selcukbiricik F, Yilmaz M, Erturk K, Murat Sarici A, Gulturk I, Ayhan M, Tural D. Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study. Melanoma Res. 2021 Oct 1;31(5):449-455. doi: 10.1097/CMR.0000000000000744.
• Özyurt E, Özçelik S, Sürmeli H, Çelik M, Ayhan M, Özçelik M. Side effects of immune-checkpoint inhibitors: Can multiple side effects be seen in a patient? J Oncol Pharm Pract. 2022 Mar;28(2):462-465. doi: 10.1177/10781552211038136.
• Dülgar Ö, Öven BB, Atcı MM, Arıkan R, Ay S, Ayhan M, Selvi O, Ozyukseler DT, Bayram E, Özcan E, Yasin Aİ, Gümüş M. Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy? Expert Rev Anticancer Ther. 2022 Jul;22(7):773-780. doi: 10.1080/14737140.2022.2076670.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study. J Cancer Res Clin Oncol. 2022 Jun;148(6):1501-1508. doi: 10.1007/s00432-021-03748-7.
• Volume I, Kucukarda A, Atcı MM, Ayhan M, et all. Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study. Tumori. 2022 Feb;108(1):19-25. doi: 10.1177/03008916211037739.
• Dogan I, Ayhan M, Gurbuz M, et all. The frequency and prognostic significance of ABO/Rh blood groups in male breast cancer patients: A multicenter study. Medicine (Baltimore). 2022 Sep 2;101(35):e30147. doi: 10.1097/MD.0000000000030147.
• Ozcelik M, Oyman A, Cil I, Duzgun O, Ozkan OF, Ayhan M. Cytoreductive Surgery versus Systemic Chemotherapy alone in Isolated Peritoneal Carcinomatosis of Colorectal Origin. J Coll Physicians Surg Pak. 2021 Nov;31(11):1308-1313. doi: 10.29271/jcpsp.2021.11.1308.
• Başoğlu T, Sakin A, Erol C, Ayhan M, et all. Real life experienceof patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study. J Chemother. 2022 May 17:1-8. doi: 10.1080/1120009X.2022.2073159.
• Özdemir Ö, Zengel B, Yildiz Y, Ayhan M, et all. The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study. Anticancer Drugs. 2022 Aug 1;33(7):663-670. doi: 10.1097/CAD.0000000000001310.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study). J Cancer Res Clin Oncol. 2022 Sep 1. doi: 10.1007/s00432-022-04252-2.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study. Future Oncol. 2022 Jul;18(23):2573-2582. doi: 10.2217/fon-2022-0083.
• Topcu A, Atci MM, Secmeler S, Besiroglu M, Ayhan M, Ozkan M, Bozkurt O, Urakci Z, Ay S, Geredeli C, Yasin AI, Turk HM. Efficacy of trastuzumab and potential risk factors on survival in patients with HER2-positive metastatic gastric cancer. Future Oncol. 2021 Nov;17(31):4157-4169. doi: 10.2217/fon-2021-0398.
• Bilgin B, Sendur MAN, Yucel S, Ayhan M, et all. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study. J Cancer Res Clin Oncol. 2021 Jul;147(7):2145-2152. doi: 10.1007/s00432-020-03501-6.
• Atci MM, Akagunduz B, Demir M, Arikan R, Ay S, Ozer M, Ayhan M, Cil I, Demir N, Ozyurt N, Karakaya G, Cevik GT, Onder AH, Selvi O, Sakin A. The impact of adjuvant oxaliplatin and tumor sidedness on the overall survival of stage IIB colon cancer patients: a multicentre study. J Chemother. 2023 Feb;35(1):19-28. doi: 10.1080/1120009X.2022.2040770.
• Tataroglu Ozyukseler D, Ay S, Turan M, Alkan G, Ayhan M, Surmeli H, et al. The Systemic Inflammation Response Index as a Prognostic Marker in Advanced Pancreatic Cancer. EJMI 2022;6(3):367–373.
• Yıldız F, Ayhan M, Demir H, et all. Comparing the efficacy of cabazitaxel in secondline and third-Line treatment of metastatic castration-resistant prostate cancer: a multi-center experience from Turkey. International Journal of Contemporary Medical Research, 7(9), 112-116.,Doi: 10.21276/ijcmr.2020.7.9.30
• Terzioğlu K, Ayhan M. Distribution of allergens detected on patch tests of patients with allergic contact dermatitis and investigation of their atopic background. Annals of Medical Research, 29(5), 422-426., doi: 10.5455/annalsmedres.2021.07.490
• Arikan R, Atci MM, Ay S, Ayhan M, et all Prognostic significance of mucinous histology in left sided metastatic colorectal cancers with wild type RAS and evaluation of backbone chemotherapy regimens. Oncol Lett. 2023 Apr 5;25(5):208. doi: 10.3892/ol.2023.13795.
• Almuradova E, Yalcin S, Arıkan R, Ayhan M, Demir H, Cevik GT, Karaca M, Petekkaya I, Karabulut B. Survival of Patients With Metastatic Rectum Cancer Who Underwent Metastasectomy Following Conversion Chemotherapy Sans Pelvic Radiotherapy: A Turkish Oncology Group Study. Cureus 2023 May 17;15(5):e39119. doi: 10.7759/cureus.39119.
• Topcu A, Besiroglu M, Atci MM, Ayhan M, et all. Second-line Therapy after Trastuzumab Failure in HER2-Positive Metastatic Gastric Cancer: A Real-life Data. EJMI 2023;7(2):153–161. DOI: 10.14744/ejmi.2023.22720
• Book Writing:
• Drug interactions and side effects of targeted agents, Section name: (Small molecule tyrosine kinase inhibitors; ROS-1 targeted therapies (Crizotinib, Seritinib)) (2021)., AYHAN MURAT, Turkish Clinics Journal of Medical Sciences, Editor: Mehmet Aliustaoglu, Publishing number:1, Number of Pages 92, ISBN:978-625-401- 466-6, Turkish
• Approach to gastrointestinal stromal tumors and neuroendocrine tumors, Department name: (Medical approach in primary non-gastrointestinal neuroendocrine tumors) (2020)., AYHAN MURAT, Akademisyen Yayınevi, Editor: Anılır Ender, Number of editions: 1, Number of Pages 382, ISBN: 9786052585719, Turkish
• Internal medicine emergencies, Department name: (Oncological emergencies) (2022)., YILDIRIM SEDAT, AYHAN MURAT, Efe Academic Publishing, Editor: Serdar Olt, Number of editions: 1, Number of Pages 232, ISBN: 978-625-8324-66- 2, Turkish
• Physicians' chemotherapy cancer drug manual 2020, Section name: (Common chemotherapy regimens in clinical practice) (2022)., SÜMBÜL AHMET TANER, ALKAN ALI, AKSOY ASUDE, AYHAN MURAT, et all, Türkiye Klinikleri Journal of Medical Sciences, Editor: EDWAR CHU, VINCENT T. DEVITA, SAADDETIN KILIÇKAP, CEMIL BILIR, SELÇUK SEBER, Number of editions: 1, Number of pages 772, ISBN: 978-625-401-290- 7, Turkish (Book Translation)

Marmara University Faculty of Medicine, Department of Radiation Oncology Specialization training: 2012 -2016

Marmara University Faculty of Medicine (English) Undergraduate: 2004-2011

Sixteen Numbered Shirvan School (Azerbaijan) High School: 1998 -2004

Surgical Oncologist

Over 15,000 successfully conducted cancer surgeries of various complexities

Education

• 1996 — Bachelor of Medicine, Mysore University, India.
• 2002 — Doctor of Medicine, radiotherapy, Banaras Hindu University, India.
• 2004 — Diplomate of National Board, radiotherapy, National Board Of Examination.

Membership

• Association of radiation oncology of India.
• Society for Neuro-Oncology.
• Bangalore Oncology Group.
• Indian Association of Hyperthermia Oncology.

この医師は、HCG Manavata Cancer Centreで12年間の経験を持つ熟練した核医学専門医です。医師は、さまざまな核スキャン、PET-CTスキャン、および核心臓病学サービスを専門としており、放射性ヨウ素およびLu-177 RN療法において熟練しています。キャリアの中で、医師は30,000件以上のPETスキャンを管理し、1,000人以上の甲状腺癌患者を治療してきました。さらに、医師はさまざまな医学雑誌に論文を発表することで、この分野に貢献しています。

この医師は、高度な技術を持つ腫瘍専門医であり、固形腫瘍、小児腫瘍、血液悪性腫瘍を含むさまざまな癌の治療を専門としています。彼女は、ウィップル手術などの保守的および外科的治療の両方に精通しています。<\/p>

彼女はLady Hardinge Medical CollegeでMBBSを取得し、Maulana Azad Medical Collegeで内科のMDを取得しました。その後、Tata Memorial HospitalでDM医療腫瘍学を追求し、そこでコンサルタントとしても勤務しました。<\/p>

彼女は国際的および国内の腫瘍学会に所属しており、肺、乳房、婦人科、泌尿生殖器の癌に関する専門知識を持ち、免疫療法とメトロノミック療法に特に関心を持っています。<\/p>

Dr. ラリットは、PuneのMIMERでMBBSを取得し、名門のGMC PanajiでMSを取得しました。これに続いて、彼はコルカタのタタ医療センターで2年間、外科腫瘍学のフェローシップを追求し、消化器癌に特に重点を置いたオンコサージェリーの訓練を受けました。彼はコルカタのタタ医療センターでいくつかのオリジナル研究の共同主任研究者として働きました。TMC、コルカタの後、彼は国立癌研究所およびオーランガバード政府癌病院の准教授を務めました。彼の豊富な10年間の外科経験で、彼は10,000以上の大手術を成功させました。彼は多くの国内外の出版物を持っています。彼の主な関心は、優れた結果をもたらす低侵襲癌手術にあります。彼は患者に親しみやすく倫理的なアプローチで知られています。 

医師はShyam Shah Medical Collegeで内科の医学博士号を取得し、同部門でシニアレジデンシーを務めました。その後、Jawaharlal Nehru Cancer Hospitalで医療腫瘍学のレジストラとして勤務しました。医師はIndraprastha Apollo Hospitalで医療腫瘍学のDNBトレーニングを修了しました。

シニアレジデンシーの期間中、医師はAIIMSで開催されたInternational Winter School of Oncologyで講義を行い、American Society of Clinical OncologyによるGastrointestinal Cancer Symposiumで胃がんに関する研究を発表しました。医師はがんの分子基盤と標的療法を専門としています。

医師はムンバイのTata Memorial Hospitalで外科腫瘍学の訓練を受け、エディンバラのRoyal College of SurgeonsでMRCSを修了しました。2000年に実践を開始し、2007年にCurie Manavata Cancer Centreを設立しました。19年の経験を持ち、医師は50,000件以上の癌手術を行い、200以上の臨床試験に参加しました。医師は多くの国際的および国内の出版物を持つ著者です。乳房および胸部外科腫瘍学を専門とし、医師はMUHSでDNB Superspecialty Surgical OncologyおよびBreast Surgeryの教授です。<\/p>

Huseyin Bektas - Professor, Doctor of Medical Sciences, Oncosurgeon. He is the author of numerous scientific publications. Member of the Association of Hepatobiliary and Pancreatic Surgery. Teacher at the Hanover School of Medicine and Chief Physician of the Department of General, Visceral and Oncological Surgery at the Bremen-Mitte Hospital.

Oncologist

Onco-surgeon. Specializes in gastrointestinal tract surgery and breast cancer.

エドアルド・ベレッタ博士は一般外科の専門家です。ミラノのサンラファエレ病院の内分泌外科部門の部門長

彼は、甲状腺および副甲状腺の病気の治療に何年もの経験を持ち、年間200を超える手術を制限的かつ低侵襲技術を用いて行っています。彼は、腹腔鏡技術を用いて副腎疾患の外科的治療を行っています。

ベレッタ教授はまた、一般外科における彼の経験を、消化器病理（食道、胃、結腸、肝臓、胆道、および膵臓）、腹壁、および複雑な腫瘍性疾患の治療の組織化に成功裏に適用しています。

ヨルク・グロティッケ教授は、ブレーメン・ミッテ病院の腫瘍学および血液学センターの主任医師です。医師は、血液悪性腫瘍および消化管腫瘍の治療を専門としています。

専門分野

1987年に教授は免疫学の専門研修を修了しました。1993年に、ヨルク・グロティッケはブレーメン・ミッテ病院の内科で博士号を取得しました。2007年にヨルク・グロティッケ博士はブレーメン・ミッテ内科センターの上級医師になりました。2005年以降、医師は腫瘍学センターを指揮し、ブレーメン腫瘍学会で革新的な癌治療について講義を行っています。

会員

• ドイツ血液学および医療腫瘍学会;
• ドイツ根拠に基づく医療ネットワーク;
• ドイツ癌学会;
• ブレーメン癌学会。

予約を取る

グロティッケ教授との予約を取るには、ウェブサイトにリクエストを送信してください。Bookimedの医師が連絡して相談の適切な時間と日付を設定します。

医療セカンドオピニオンを取得する

相談のためにドイツに行く必要はありません。ヨルク・グロティッケ教授は遠隔での相談を提供しています。診断や治療計画に疑問がある場合、また有名な医師からの推薦を受けたい場合、セカンドオピニオンを取得してください。